Why insider trading matters?
If management teams do not own any relevant stakes in the companies they guide, they may not be focused on creating wealth for shareholders to the same degree, compared to those that see their personal wealth increase when share prices rise.
Humanigen, Inc., a biopharmaceutical company, develops proprietary monoclonal antibodies for immunotherapy and oncology treatments. The company's lead product candidate is Lenzilumab, a monoclonal antibody that targets and neutralizes granulocyte-macrophage colony-stimulating factor, which is in Phase I/II clinical trial in patients with chronic myelomonocytic leukemia, and for the treatment of juvenile myelomonocytic leukemia. Humanigen, Inc. was founded in 2000 and is based in Burlingame, California.
| Trade Date | Insider | Title | Buy/Sell | #Shares | Price | Value | Option |
|---|---|---|---|---|---|---|---|
| 2021-01-20 | NOMIS BAY LTD. | 10%-Owner | Sell | 8,500 | $20.29 | $172,423 | No |
| 2021-01-19 | NOMIS BAY LTD. | 10%-Owner | Sell | 105,000 | $18.94 | $1,989,020 | No |
| 2021-01-12 | NOMIS BAY LTD. | 10%-Owner | Sell | 25,000 | $18.67 | $466,650 | No |
| 2020-12-28 | NOMIS BAY LTD. | 10%-Owner | Sell | 500 | $22.20 | $11,101 | No |
| 2020-12-22 | NOMIS BAY LTD. | 10%-Owner | Sell | 50,000 | $20.02 | $1,000,985 | No |
| 2020-12-24 | NOMIS BAY LTD. | 10%-Owner | Sell | 53,401 | $21.24 | $1,134,104 | No |
| 2020-12-22 | NOMIS BAY LTD. | 10%-Owner | Sell | 50,000 | $50000.00 | $2,500,000,000 | No |
| 2020-12-21 | NOMIS BAY LTD. | 10%-Owner | Sell | 87,700 | $16.82 | $1,474,766 | Yes |
| 2020-08-10 | NOMIS BAY LTD. | 10%-Owner | Sell | 17,100 | $5.04 | $86,098 | No |
| 2020-07-28 | NOMIS BAY LTD. | 10%-Owner | Sell | 10,000 | $5.66 | $56,550 | No |
| 2020-07-20 | NOMIS BAY LTD. | 10%-Owner | Sell | 300,000 | $5.00 | $1,500,190 | No |
| 2020-06-30 | NOMIS BAY LTD. | 10%-Owner | Sell | 3,000 | $4.91 | $14,739 | No |
| 2020-06-16 | NOMIS BAY LTD. | 10%-Owner | Sell | 65,000 | $5.63 | $365,798 | No |
| 2020-06-10 | NOMIS BAY LTD. | 10%-Owner | Sell | 516,260 | $2.62 | $1,353,281 | No |
| 2018-02-27 | NOMIS BAY LTD. | 10%-Owner | Buy | 29,893,424 | $0.28 | $8,370,159 | No |
| 2018-02-27 | Chappell Dale | 10%-Owner | Buy | 32,028,669 | $0.09 | $3,001,086 | No |
| 2017-08-30 | NOMIS BAY LTD. | 10%-Owner | Sell | 38,900 | $0.46 | $17,894 | No |
| 2016-08-26 | Shkreli Martin | 10%-Owner | Sell | 2,222,929 | $3.10 | $6,891,080 | No |
| 2015-12-16 | Anthion Partners II LLC | 10%-Owner | Buy | 6,820 | $29.32 | $199,962 | No |
| 2015-12-16 | Fernandez Thomas Edward | Director | Buy | 6,821 | $29.32 | $199,992 | No |
| 2015-12-16 | BIESTEK MAREK | Director | Buy | 10,000 | $29.32 | $293,200 | No |
| 2015-12-16 | Harrison Michael Wayne | Director | Buy | 1,705 | $29.32 | $49,991 | No |
| 2015-12-16 | Anthion Partners II LLC | 10%-Owner | Buy | 6,820 | $29.32 | $199,962 | No |
| 2015-11-24 | Shkreli Martin | Chief Executive Officer | Buy | 5,000 | $38.15 | $190,750 | No |
| 2015-11-20 | Shkreli Martin | Chief Executive Officer | Buy | 5,000 | $18.88 | $94,400 | No |
| 2015-11-18 | Anthion Partners II LLC | 10%-Owner | Buy | 300,000 | $2.13 | $639,000 | No |
| 2015-11-18 | BIESTEK MAREK | nan | Buy | 40,000 | $2.04 | $81,600 | No |
| 2015-11-18 | Shkreli Martin | 10%-Owner | Buy | 440,000 | $2.02 | $888,800 | No |
| 2015-11-17 | BIESTEK MAREK | nan | Buy | 200,000 | $1.68 | $335,450 | No |
| 2015-11-17 | Anthion Partners II LLC | 10%-Owner | Buy | 713,726 | $1.42 | $1,014,263 | No |
Insider Smart
Insider Smart